Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | LGMN | Q99538 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | TTR | P02766 | 1/20 | 0.38 |
| ▸ | CES2 | O00748 | 1/20 | 0.37 |
| ▸ | CES1 | P23141 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | SCD | O00767 | 1/20 | 0.36 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29239530 | 0.88 | GAA (0.46) | KEAP1ALDH1A1HSD17B10ALOX15MAPK10 | |
| SCHEMBL3825337 | 0.84 | GAA (0.50) | KEAP1ALDH1A1HSD17B10GAAMAPT | |
| SCHEMBL3824501 | 0.81 | GAA (0.55) | ALDH1A1ALOX15GAALMNAKDM4E | |
| SCHEMBL6646093 | 0.81 | HPGD (0.44) | ALDH1A1GAALGMNNOTUMTTR | |
| SCHEMBL225760 | 0.77 | ALDH1A1 (0.50) | ALDH1A1ALOX15GAATDP1L3MBTL1 | |
| SCHEMBL17119924 | 0.76 | F2RL1 (0.46) | KEAP1NOTUMKMT2AL3MBTL1 | |
| SCHEMBL17535830 | 0.73 | SLC6A3 (0.44) | ALDH1A1MAPK10MAPTKDM4EMEN1 | |
| SCHEMBL28965486 | 0.72 | ALDH1A1 (0.57) | KEAP1ALDH1A1HSD17B10ALOX15GAA | |
| SCHEMBL11100186 | 0.72 | MYC (0.53) | ALDH1A1HSD17B10NOTUMLMNAMAPT | |
| SCHEMBL11100139 | 0.72 | KDM4E (0.56) | ALDH1A1HSD17B10ALOX15GAALGMN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1727551-B1 | PHARMACEUTICAL COMPOSITION COMPRISING A BENZODIAZEPINE DERIVATIVE AND A INHIBITOR OF THE RSV FUSION PROTEIN | ARROW THERAPEUTICS LTD (GB) | 2009-09-09 | — | — | EP | disclosed |
| US-20080139536-A1 | Benzodiazepines for Treating or Preventing Rsv Infection | NOVARTIS PHARMACEUTICALS CORPORATION (US) | 2008-06-12 | — | — | US | disclosed |
| US-20070185096-A1 | Pharmaceutical composition comprising a benzodiazepine derivative and an inhibitor of the rsv fusion protein | NOVARTIS PHARMACEUTICALS CORPORATION (US) | 2007-08-09 | — | — | US | disclosed |
| CN-1933841-A | Pharmaceutical composition comprising a benzodiazepine derivative and an inhibitor of the rsv fusion protein | ARROW THERAPEUTICS LTD (GB) | 2007-03-21 | — | — | CN | disclosed |
| EP-1740185-A1 | BENZODIAZEPINES FOR TREATING OR PREVENTING RSV INFECTION | Arrow Therapeutics Limited (GB) | 2007-01-10 | — | — | EP | disclosed |
| EP-1727551-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A BENZODIAZEPINE DERIVATIVE AND A INHIBITOR OF THE RSV FUSION PROTEIN | Arrow Therapeutics Limited (GB) | 2006-12-06 | — | — | EP | disclosed |
| WO-2005089770-A1 | BENZODIAZEPINES FOR TREATING OR PREVENTING OR PREVENTING RSV INFECTION | ARROW THERAPEUTICS LIMITED (GB) | 2005-09-29 | — | — | WO | disclosed |
| WO-2005089771-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A BENZODIAZEPINE DERIVATIVE AND A INHIBITOR OF THE RSV FUSION PROTEIN | ARROW THERAPEUTICS LIMITED (GB) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185096-A1 | Pharmaceutical composition comprising a benzodiazepine derivative and an inhibitor of the rsv fusion protein | GABRP, TSPO, GABRA1 | KEAP1 3765/4885ALDH1A1 3840/4885HSD17B10 3109/4885 |
| US-20080139536-A1 | Benzodiazepines for Treating or Preventing Rsv Infection | CNR1, CBR1, CBR3 | KEAP1 1662/4885ALDH1A1 1328/4885HSD17B10 1026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.